Cadmus Rich
Director/Board Member bij Sustained Nano Systems LLC
Vermogen: 51 520 $ op 31-03-2024
Profiel
Cadmus Collins Rich is currently a Director at Sustained Nano Systems LLC.
He was previously a Director at North Carolina Specialty Hospital LLC and Treasurer & Director at National Society to Prevent Blindness.
He served as VP-Medical Affairs & Clinical Development at Inotek Pharmaceuticals Corp.
from 2015 to 2017.
From 2017 to 2023, he was the Chief Medical Officer, Head-Research & Development at Aura Biosciences, Inc. Dr. Rich has an undergraduate degree from Case Western Reserve University, an MBA from Regis University, and a doctorate from UNC School of Medicine.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
AURA BIOSCIENCES INC
0.01% | 31-03-2023 | 6 563 ( 0.01% ) | 51 520 $ | 31-03-2024 |
Actieve functies van Cadmus Rich
Bedrijven | Functie | Begin |
---|---|---|
Sustained Nano Systems LLC
Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Director/Board Member | - |
Eerdere bekende functies van Cadmus Rich
Bedrijven | Functie | Einde |
---|---|---|
AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 16-10-2023 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Chief Tech/Sci/R&D Officer | 01-09-2017 |
North Carolina Specialty Hospital LLC | Director/Board Member | - |
National Society to Prevent Blindness
National Society to Prevent Blindness Miscellaneous Commercial ServicesCommercial Services National Society to Prevent Blindness operates as an eye health and safety organization. It offers services for amblyopia, AMD, cataract, central retinal vein occlusion, colour blindness, conjunctivitis, diabetic eye disease and macular enema, dry eye, floaters, glaucoma, refractive eye, retinal tears and detachments, retinitis pigments and strabismus. The company was founded in 1908 and is headquartered in Chicago, IL. | Director/Board Member | - |
Opleiding van Cadmus Rich
Case Western Reserve University | Undergraduate Degree |
Regis University | Masters Business Admin |
UNC School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
North Carolina Specialty Hospital LLC | |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
National Society to Prevent Blindness
National Society to Prevent Blindness Miscellaneous Commercial ServicesCommercial Services National Society to Prevent Blindness operates as an eye health and safety organization. It offers services for amblyopia, AMD, cataract, central retinal vein occlusion, colour blindness, conjunctivitis, diabetic eye disease and macular enema, dry eye, floaters, glaucoma, refractive eye, retinal tears and detachments, retinitis pigments and strabismus. The company was founded in 1908 and is headquartered in Chicago, IL. | Commercial Services |
Sustained Nano Systems LLC
Sustained Nano Systems LLC Miscellaneous Commercial ServicesCommercial Services Sustained Nano Systems LLC is a company that develops products for post-cataract surgery treatment. The company is based in Westhampton Beach, NY and was founded by Barry M. Libin, who has been the CEO since incorporation. The company's products include dex-sa, which delivers dexamethasone to the subconjunctival space to treat postoperative inflammation and pain, and lat-la, a single extraocular injectable administration of a six-month release prostaglandin analog for glaucoma treatment. The company also develops SNS ret-la, which prevents blood vessel growth for over a year in a standard rabbit model of corneal angiogenesis. | Commercial Services |